Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2018-05-09 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BT_2018-05-09_AGO-AGE 2018_Droits actionnaires_EN.pdf
AGM Information Classification · 98% confidence The document explicitly discusses the rights of shareholders regarding the upcoming Ordinary and Extraordinary General Meetings (AGM/EGM) scheduled for June 13, 2018. It details procedures for shareholders to include items on the agenda, submit proposals, and ask written questions, citing specific articles of the Belgian Company Code (533ter and 540). This content is directly related to the preparation and conduct of a general meeting, specifically concerning shareholder participation and voting rights information prior to the meeting. This aligns best with the definition of materials shared during or in preparation for an Annual General Meeting (AGM-R), as it outlines the rules governing shareholder input for that meeting.
2018-05-09 English
BT_2018-06-01_AGO-AGE 2018_Procuration_FR_modifiee.pdf
AGM Information Classification · 98% confidence The document is titled 'PROCURATION' (Proxy) and details the process for shareholders to appoint a representative ('mandataire') to vote at an upcoming 'assemblée générale ordinaire et extraordinaire' (Ordinary and Extraordinary General Meeting) scheduled for June 13, 2018. The agenda items explicitly cover the approval of the annual report, auditor's report, remuneration report, annual accounts for the year ended December 31, 2017, discharge of directors, and capital structure changes (reduction of share premium/capital and renewal of authorized capital). The core function of this document is to solicit shareholder votes and provide the necessary mechanism (the proxy form) for representation at the AGM. This aligns perfectly with the definition of materials shared during the Annual General Meeting (AGM-R), which often includes the proxy form itself or related voting materials, although it is distinct from the Proxy Solicitation & Information Statement (PSI) which usually contains the full background information for the vote. Given the explicit focus on appointing a proxy for the AGM, AGM-R is the most appropriate classification, as it covers AGM materials.
2018-05-09 French
BT_2018-05-09_AGO-AGE 2018_Procuration_EN.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is explicitly titled 'PROXY FORM' and details the procedures, agenda items, and proposed resolutions for an upcoming 'annual general meeting' (AGM) scheduled for June 13, 2018. It includes sections for shareholders to appoint a proxy holder and vote on matters such as approving the annual report, auditor's report, remuneration report, granting discharge to directors, and making capital structure changes (Ordinary and Extraordinary general meetings). This content is characteristic of materials used to solicit shareholder votes ahead of a general meeting, which aligns directly with the definition of Proxy Solicitation & Information Statement (PSI). While it discusses the AGM, it is the solicitation document, not the AGM presentation (AGM-R) or the final voting results (DVA).
2018-05-09 English
BT_2018-06-01_AGO-AGE 2018_Convocation_FR_modifiee.pdf
AGM Information Classification · 99% confidence The document is explicitly titled "CONVOCATION À L'ASSEMBLÉE GÉNÉRALE ORDINAIRE ET À L'ASSEMBLÉE GÉNÉRALE EXTRAORDINAIRE" (Notice of Ordinary General Meeting and Extraordinary General Meeting). It details the agenda for both meetings, including the submission of the annual report, approval of remuneration reports, discharge of directors, and various capital structure changes (reduction of capital, renewal of authorized capital, issuance of warrants). This content is characteristic of materials distributed to shareholders in preparation for an Annual General Meeting (AGM). Although it mentions the annual report (which would be a 10-K if it were the US filing), the document itself is the formal notice and agenda for the meeting, making 'AGM-R' (AGM Information) the most appropriate classification, as it contains the materials and context for the meeting.
2018-05-09 French
BT_Plan de warrants_EN.pdf
Capital/Financing Update Classification · 85% confidence The document is titled "BONE THERAPEUTICS SA WARRANT PLAN" and details the terms, definitions, rights, characteristics, and exercise procedures for warrants granted to selected participants (Directors, Employees, Consultants). This document outlines a specific equity incentive scheme, which falls under the category of capital structure or financing-related documentation, but more specifically, it details the structure of an employee/director incentive plan. Reviewing the definitions: - 10-K/IR: Not a periodic financial report. - ER/MRQ: Not an earnings release. - CT: Not a transcript. - DIV/NAV: Not a dividend or NAV announcement. - DIRS: Not a director's dealing report. - DEF 14A: While related to compensation, this is the plan document itself, not the formal remuneration disclosure. This document describes the mechanism for issuing capital (shares via warrants) and is fundamentally about the company's capital structure and financing instruments offered to key personnel. The closest fit among the provided codes is 'Capital/Financing Update' (CAP), as warrant plans are a form of capital management/financing tool. However, given the highly specific nature of the content (a detailed plan document for warrants), it often falls under general corporate governance or capital structure documentation. Since it details the terms of issuing shares upon exercise, it relates directly to capital changes. If a more specific 'Equity Incentive Plan Document' existed, that would be ideal. In the absence of such a code, 'CAP' (Capital/Financing Update) is the most appropriate category as it governs the issuance of future capital instruments (warrants leading to shares). Alternatively, since it is a formal plan document approved by the Board, it could be considered Governance Information (CGR). However, the core subject is the issuance and terms of warrants, which is a capital event. Given the options, CAP seems slightly better than CGR, but let's re-evaluate against the definitions. This is a foundational document detailing the terms of a capital instrument (warrants). It is not a simple announcement of financing (CAP), but the detailed plan itself. Since it is a formal plan document detailing rights and characteristics, it aligns well with the scope of governance/structural documents. Since it is not a standard regulatory filing (10-K, AR, IR), and it's not a simple announcement (RPA/RNS), and it's not about remuneration disclosure (DEF 14A), I will classify it as a Capital/Financing Update (CAP) as it dictates the terms under which new capital (shares) will be issued, which is a primary function of financing activities.
2018-05-09 English
BT_Special Report from the Board - warrants.pdf
Capital/Financing Update Classification · 98% confidence The document is titled "RAPPORT SPECIAL DU CONSEIL D'ADMINISTRATION ETABLI CONFORMEMENT AUX ARTICLES 583, 596 ET 598 DU CODE DES SOCIETES" (Special Report of the Board of Directors established in accordance with Articles 583, 596 and 598 of the Companies Code). It explicitly discusses the proposal for the issuance of subscription rights (Warrants) to employees and directors, the suppression of preferential subscription rights, and details the projected dilution consequences for existing shareholders regarding voting rights, profits, and equity. This content is highly specific to corporate actions involving capital structure changes and shareholder rights, which aligns best with the 'Capital/Financing Update' (CAP) category, as it details the mechanics and impact of issuing new securities (Warrants) and the associated dilution. While it involves management proposals, its core focus is the capital transaction itself, making CAP more precise than MANG or SHA (which is usually for direct share issues/splits). It is a detailed report, not just an announcement of a report (RPA/RNS).
2018-05-09 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.